Servier
64
Description
Founded 70 years ago to serve health, Servier is an international pharmaceutical group governed by a Foundation, which aspires to have a significant societal impact for patients and for a sustainable world. Its unique governance model guarantees its independence and allows it to fully serve its vocation with a long-term vision: being committed to therapeutic progress for the benefit of patients. The employees who make up the Group are committed to this common vocation, a daily source of inspiration.
A global leader in cardio-metabolism and venous diseases, Servier has made a major shift into oncology, which constitutes a new strategic growth pillar. The Group dedicates nearly 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology constitutes a future growth driver. In this area, Servier focuses on a limited number of pathologies in which a precise characterization of patients makes it possible to offer a targeted therapeutic response, thanks to precision medicine. To promote access to quality healthcare for all at a lower cost, the Group also offers a range of generic medicines covering the majority of pathologies, relying on strong brands in France, Eastern Europe, and Brazil. In all these areas, the Group integrates the patient's voice at every stage of the medicine's life cycle.
Servier, whose headquarters are based in France, relies on committed teams and a solid geographical presence, with medicines available in nearly 140 countries. The Group achieved a turnover of €5.9 billion in 2023/2024 and €1.3 billion in EBITDA (22.2%) in 2024. It currently has more than 22,000 employees worldwide.